MedTrace Logo

Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer

NCT02923258 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2024-06-20

No results posted yet for this study

Summary

This is a randomized,controled, phase II, open label study of postoperative concurrent chemoradiotherapy with Docetaxel versus Cisplatin for high-risk squamous cell carcinoma of the oral cavity cancer.The primary purpose of this study is to evaluate the efficacy of concurrent chemoradiotherapy with docetaxel in OCC patients.

Conditions

  • Oral Cavity Squamous Cell Carcinoma

Interventions

DRUG

Docetaxel

20mg/m2/w

DRUG

Cisplatin

100mg/m2/q3w

RADIATION

IMRT

a total dose of 60Gy in 30fractions over 6 weeks

Sponsors & Collaborators

  • Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

    lead OTHER

Principal Investigators

  • Guopei Zhu · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-21
Primary Completion
2022-02-28
Completion
2023-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02923258 on ClinicalTrials.gov